Skip to main
ANTX
ANTX logo

ANTX Stock Forecast & Price Target

ANTX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

AN2 Therapeutics Inc. has demonstrated promising results from its Phase 2 trials of epetraborole, which has shown good safety and tolerability, as well as potential benefits for quality of life in patients with non-tuberculous mycobacterial (NTM) infections. The positive impact on cough frequency and intensity, coupled with strong pre-clinical data supporting its efficacy for treating more challenging forms of NTM, positions epetraborole as a potentially significant development in the therapeutic landscape. Overall, the company's commitment to advancing its boron-based compounds for various infectious diseases and oncology, alongside encouraging clinical outcomes, bolsters a positive long-term outlook for its stock.

Bears say

AN2 Therapeutics Inc faces significant challenges, highlighted by poor clinical trial results for its lead candidate, epetraborole, which raises concerns about the efficacy and safety of its drug pipeline. The company has a history of financial losses and lacks a track record of profitability, suggesting it may struggle to secure favorable partnerships or successfully commercialize its products. Moreover, potential litigation and regulatory risks further complicate AN2's ability to protect its market exclusivity and effectively navigate competitive pressures, painting a bleak outlook for its future.

ANTX has been analyzed by 6 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AN2 Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AN2 Therapeutics Inc (ANTX) Forecast

Analysts have given ANTX a Buy based on their latest research and market trends.

According to 6 analysts, ANTX has a Buy consensus rating as of Jul 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AN2 Therapeutics Inc (ANTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.